In this study, we also noted that NSCLCs with very high PD-L1 levels greater than or equal to 90% are enriched in BRCA2 and KDM5C loss-of-function mutations, which have been previously associated with increased mutational burden, increased CD8+ T cell infiltration, effector T-cell signatures, and improved outcomes to immunotherapy in NSCLC.20, 21, 22, 23 By contrast, NSCLCs with a PD-L1 TPS of 50% to 89% were enriched in loss-of-function mutations in STK11 and SMARCA4 and have higher aneuploidy levels, which are mediators of primary resistance to PD-(L)1 blockade in NSCLC.24 This evidence concerns the gene STK11 and non-small cell lung carcinoma.